Livalo

Livalo is a brand name of pitavastatin, approved by the FDA in the following formulation(s):

LIVALO (pitavastatin calcium - tablet; oral)

• 
  Manufacturer: KOWA CO
  
  Approval date: August 3, 2009
  
  Strength(s): EQ 1MG BASE, EQ 2MG BASE, EQ 4MG BASE ^[RLD]

Has a generic version of Livalo been approved?

No. There is currently no therapeutically equivalent version of Livalo available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Livalo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Quinoline analogs of mevalonolactone and derivatives thereof
  Patent 5,753,675
  Issued: May 19, 1998
  Inventor(s): Wattanasin; Sompong
  Assignee(s): Novartis Pharmaceuticals Corporation
  Quinoline analogs of mevalonolactone of the following formula are useful as anti-cholesterol synthesis agents: ##STR1## where the substituents are as defined in the specification.
  
  Patent expiration dates:
  
  
  • May 19, 2015
    
    ✓ 
    Patent use: ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Quinoline type mevalonolactones
  Patent 5,854,259
  Issued: December 29, 1998
  Inventor(s): Fujikawa; Yoshihiro & Suzuki; Mikio & Iwasaki; Hiroshi & Sakashita; Mitsuaki & Kitahara; Masaki
  Assignee(s): Nissan Chemical Industries Ltd.
  Described herein are mevalonolactone derivatives having a quinoline ring of formula (I) ##STR1## wherein the R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, Y and Z variables are described therein.
  
  Patent expiration dates:
  
  
  • December 29, 2015
    
    ✓ 
    Drug product
  
  



• 
  Quinoline type mevalonolactones
  Patent 5,856,336
  Issued: January 5, 1999
  Inventor(s): Fujikawa; Yoshihiro & Suzuki; Mikio & Iwasaki; Hiroshi & Sakashita; Mitsuaki & Kitahara; Masaki
  Assignee(s): Nissan Chemical Industries Ltd.
  A compound of the formula ##STR1## Z=--CH(OH)--CH.sub.2 --CH(OH)--CH.sub.2 --COO.1/2Ca have HMG--CoA inhibiting effects, making them useful as inhibitors of cholesterol biosynthesis. The compound may be prepared as a pharmaceutical for reducing hyperlipidemia, hyperlipoproteinemia or atherosclerosis.
  
  Patent expiration dates:
  
  
  • January 5, 2016
    
    ✓ 
    Patent use: ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
    ✓ 
    Drug substance
  
  



• 
  Stable pharmaceutical composition
  Patent 6,465,477
  Issued: October 15, 2002
  Inventor(s): Toyojiro; Muramatsu & Katsumi; Mashita & Yasuo; Shinoda & Hironori; Sassa & Hiroyuki; Kawashima & Yoshio; Tanizawa & Hideatsu; Takeuchi
  Assignee(s): Kowa Company, Ltd.
  Nissan Chemical Industries, Ltd.
  Disclosed is a pharmaceutical composition comprising (E)-3,5-dihydroxy-7-[4′-4″-fluorophenyl-2′-cyclopropyl-quinolin-3′-yl]-6-heptenoic acid, or its salt or ester, of which the aqueous solution or dispersion has pH of from 6.8 to 8. The composition has good time-dependent stability and has no change in its outward appearance even after having been stored long.
  
  Patent expiration dates:
  
  
  • December 20, 2016
    
    ✓ 
    Drug product
  
  



• 
  Hyperlipemia therapeutic agent
  Patent 7,022,713
  Issued: April 4, 2006
  Inventor(s): Aoki; Taro & Yamaguchi; Junji & Sasaki; Yusuke
  Assignee(s): KOWA Co., Ltd.
  Nissan Chemical Industries, Ltd.
  The present invention relates to a hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid or an ester derivative thereof as effective ingredients. According to the present invention, a type IIb and type IV hyperlipemia therapeutic agent having an excellent effect of lowering the cholesterol and triglyceride in blood is provided.
  
  Patent expiration dates:
  
  
  • February 19, 2024
    
    ✓ 
    Patent use: ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • August 3, 2014 - NEW CHEMICAL ENTITY
  
  

See also...

• Livalo Consumer Information (Drugs.com)
• Livalo Consumer Information (Wolters Kluwer)
• Livalo Consumer Information (Cerner Multum)
• Livalo Advanced Consumer Information (Micromedex)
• Livalo AHFS DI Monographs (ASHP)
• Pitavastatin Consumer Information (Wolters Kluwer)
• Pitavastatin Consumer Information (Cerner Multum)
• Pitavastatin Advanced Consumer Information (Micromedex)
• Pitavastatin Calcium AHFS DI Monographs (ASHP)